• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cox 比例风险模型在恢复大型分子肿瘤药物混杂暴露反应关系的真实情况方面的性能。

Performance of Cox proportional hazard models on recovering the ground truth of confounded exposure-response relationships for large-molecule oncology drugs.

机构信息

Modeling and Simulation Group, Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2022 Nov;11(11):1511-1526. doi: 10.1002/psp4.12859. Epub 2022 Sep 16.

DOI:10.1002/psp4.12859
PMID:35988264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9662202/
Abstract

A Cox proportional hazard (CoxPH) model is conventionally used to assess exposure-response (E-R), but its performance to uncover the ground truth when only one dose level of data is available has not been systematically evaluated. We established a simulation workflow to generate realistic E-R datasets to assess the performance of the CoxPH model in recovering the E-R ground truth in various scenarios, considering two potential reasons for the confounded E-R relationship. We found that at high doses, when the pharmacological effects are largely saturated, missing important confounders is the major reason for inferring false-positive E-R relationships. At low doses, when a positive E-R slope is the ground truth, either missing important confounders or mis-specifying the interactions can lead to inaccurate estimates of the E-R slope. This work constructed a simulation workflow generally applicable to clinical datasets to generate clinically relevant simulations and provide an in-depth interpretation on the E-R relationships with confounders inferred by the conventional CoxPH model.

摘要

传统上使用 Cox 比例风险(CoxPH)模型来评估暴露-反应(E-R)关系,但当只有一个剂量水平的数据时,它揭示真实关系的性能尚未得到系统评估。我们建立了一个模拟工作流程来生成现实的 E-R 数据集,以评估 CoxPH 模型在各种情况下恢复 E-R 真实关系的性能,同时考虑了 E-R 关系混杂的两种潜在原因。我们发现,在高剂量时,当药理学效应基本饱和时,遗漏重要混杂因素是推断错误 E-R 关系的主要原因。在低剂量时,当正向 E-R 斜率是真实关系时,遗漏重要混杂因素或错误指定交互作用都会导致 E-R 斜率的估计不准确。这项工作构建了一个模拟工作流程,通常适用于临床数据集,以生成具有临床相关性的模拟,并对传统 CoxPH 模型推断的混杂 E-R 关系进行深入解释。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/513eeacec751/PSP4-11-1511-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/04a4958b9cfe/PSP4-11-1511-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/de7eefd627e5/PSP4-11-1511-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/3460c6b1694d/PSP4-11-1511-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/21d114f1e1fd/PSP4-11-1511-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/010364e60b27/PSP4-11-1511-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/513eeacec751/PSP4-11-1511-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/04a4958b9cfe/PSP4-11-1511-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/de7eefd627e5/PSP4-11-1511-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/3460c6b1694d/PSP4-11-1511-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/21d114f1e1fd/PSP4-11-1511-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/010364e60b27/PSP4-11-1511-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3277/9662202/513eeacec751/PSP4-11-1511-g003.jpg

相似文献

1
Performance of Cox proportional hazard models on recovering the ground truth of confounded exposure-response relationships for large-molecule oncology drugs.Cox 比例风险模型在恢复大型分子肿瘤药物混杂暴露反应关系的真实情况方面的性能。
CPT Pharmacometrics Syst Pharmacol. 2022 Nov;11(11):1511-1526. doi: 10.1002/psp4.12859. Epub 2022 Sep 16.
2
Applying interpretable machine learning workflow to evaluate exposure-response relationships for large-molecule oncology drugs.应用可解释机器学习工作流程评估大分子肿瘤药物的暴露-反应关系。
CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1614-1627. doi: 10.1002/psp4.12871. Epub 2022 Oct 20.
3
Towards effective machine learning in medical imaging analysis: A novel approach and expert evaluation of high-grade glioma 'ground truth' simulation on MRI.迈向医学影像分析中有效的机器学习:一种新颖的方法和对 MRI 上高级别胶质瘤“真实数据”模拟的专家评估。
Int J Med Inform. 2021 Feb;146:104348. doi: 10.1016/j.ijmedinf.2020.104348. Epub 2020 Nov 27.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study.预后建模研究中缺失协变量数据处理技术的比较:一项模拟研究。
BMC Med Res Methodol. 2010 Jan 19;10:7. doi: 10.1186/1471-2288-10-7.
6
Comparison of different parametric proportional hazards models for interval-censored data: a simulation study.不同参数比例风险模型在区间删失数据中的比较:一项模拟研究。
Contemp Clin Trials. 2013 Sep;36(1):276-83. doi: 10.1016/j.cct.2013.07.012. Epub 2013 Aug 3.
7
Fitting semiparametric additive hazards models using standard statistical software.使用标准统计软件拟合半参数加法风险模型。
Biom J. 2007 Aug;49(5):719-30. doi: 10.1002/bimj.200610349.
8
Investigation of realistic PET simulations incorporating tumor patient's specificity using anthropomorphic models: creation of an oncology database.利用人体模型对包含肿瘤患者特异性的真实 PET 模拟进行研究:创建肿瘤学数据库。
Med Phys. 2013 Nov;40(11):112506. doi: 10.1118/1.4826162.
9
Survival time prediction by integrating cox proportional hazards network and distribution function network.基于 Cox 比例风险网络和分布函数网络的生存时间预测。
BMC Bioinformatics. 2021 Apr 15;22(1):192. doi: 10.1186/s12859-021-04103-w.
10
The comparison of alternative smoothing methods for fitting non-linear exposure-response relationships with Cox models in a simulation study.在一项模拟研究中,用Cox模型拟合非线性暴露-反应关系时替代平滑方法的比较。
Int J Biostat. 2009 Jan 7;5(1):Article 2. doi: 10.2202/1557-4679.1104.

引用本文的文献

1
A prognostic framework for predicting lung signet ring cell carcinoma via a machine learning based cox proportional hazard model.基于机器学习的 Cox 比例风险模型预测肺印戒细胞癌的预后框架。
J Cancer Res Clin Oncol. 2024 Jul 25;150(7):364. doi: 10.1007/s00432-024-05886-0.
2
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019-2023) by US FDA, best practices and recommendations.罕见肿瘤治疗药物:美国 FDA 批准的药物临床药理学包(2019-2023 年)回顾、最佳实践和建议。
J Pharmacokinet Pharmacodyn. 2023 Dec;50(6):475-493. doi: 10.1007/s10928-023-09896-2. Epub 2023 Nov 4.
3

本文引用的文献

1
Application of machine learning based methods in exposure-response analysis.基于机器学习方法在暴露-反应分析中的应用。
J Pharmacokinet Pharmacodyn. 2022 Aug;49(4):401-410. doi: 10.1007/s10928-022-09802-2. Epub 2022 Mar 11.
2
The Drug-Dosing Conundrum in Oncology - When Less Is More.肿瘤学中的给药难题——少即是多。
N Engl J Med. 2021 Oct 14;385(16):1445-1447. doi: 10.1056/NEJMp2109826. Epub 2021 Oct 9.
3
Conditional distribution modeling as an alternative method for covariates simulation: Comparison with joint multivariate normal and bootstrap techniques.
Skipping a pillar does not make for strong foundations: Pharmacokinetic-pharmacodynamic reasoning behind the shape of dose-response relationships in oncology.
跳过支柱无法建立坚实的基础:肿瘤学中剂量反应关系形态背后的药代动力学-药效学推理。
CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1591-1601. doi: 10.1002/psp4.13020. Epub 2023 Sep 28.
4
A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancer.一种用于学习肿瘤药物剂量反应的多州建模和模拟框架:应用于 bintrafusp alfa 治疗非小细胞肺癌。
CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1738-1750. doi: 10.1002/psp4.12976. Epub 2023 May 11.
5
Applying interpretable machine learning workflow to evaluate exposure-response relationships for large-molecule oncology drugs.应用可解释机器学习工作流程评估大分子肿瘤药物的暴露-反应关系。
CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1614-1627. doi: 10.1002/psp4.12871. Epub 2022 Oct 20.
条件分布建模作为协变量模拟的一种替代方法:与联合多元正态和自举技术的比较。
CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):330-339. doi: 10.1002/psp4.12613.
4
Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology.肿瘤学中单克隆抗体的暴露-反应分析中的混杂因素及缓解策略。
Br J Clin Pharmacol. 2021 Jun;87(6):2493-2501. doi: 10.1111/bcp.14662. Epub 2020 Dec 7.
5
Characterizing Exposure-Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects.免疫肿瘤学及其他领域治疗性单克隆抗体的暴露-反应关系特征:挑战、观点和展望。
Clin Pharmacol Ther. 2020 Dec;108(6):1156-1170. doi: 10.1002/cpt.1953. Epub 2020 Aug 2.
6
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.在非霍奇金淋巴瘤患者中评估泊洛昔单抗与拓扑替康偶联物的两分析物群体药代动力学整合模型。
CPT Pharmacometrics Syst Pharmacol. 2020 Jan;9(1):48-59. doi: 10.1002/psp4.12482. Epub 2019 Dec 23.
7
A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma.一种机器学习方法,用于识别与晚期黑色素瘤患者纳武利尤单抗清除相关的预后细胞因子特征。
Clin Pharmacol Ther. 2020 Apr;107(4):978-987. doi: 10.1002/cpt.1724. Epub 2019 Dec 19.
8
Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling With mrgsolve: A Hands-On Tutorial.定量系统药理学和基于生理的药代动力学模型与 mrgsolve:实践教程。
CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):883-893. doi: 10.1002/psp4.12467. Epub 2019 Nov 14.
9
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.帕博利珠单抗暴露-反应评估受到癌症恶病质和分解代谢清除的关联的挑战。
Clin Cancer Res. 2018 Dec 1;24(23):5841-5849. doi: 10.1158/1078-0432.CCR-18-0415. Epub 2018 Jun 11.
10
Big Data Toolsets to Pharmacometrics: Application of Machine Learning for Time-to-Event Analysis.大数据工具集在药代动力学中的应用:机器学习在事件时间分析中的应用。
Clin Transl Sci. 2018 May;11(3):305-311. doi: 10.1111/cts.12541. Epub 2018 Mar 13.